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Background: With the acceleration of industrialization in low or middle-income nations, the prevalence of
respiratory symptoms among older adults is even more significant now in China. Contemporary treatments using
Western medicine, such as anti-inflammatory regimens, may be effective in relieving the symptoms, but may have
unexpected side effects. Some natural products may be effective in improving respiratory functions, yet their
efficacies remain to be examined in randomized, placebo-controlled studies. To evaluate the effects of Lung
Support Formula, a nutritional supplement which contains naturally derived Chinese herbal medicines, we
conducted a clinical study among older adults in Shanghai, China.
Methods: A total of 100 patients over 50 years old were recruited and blindly randomized into the treatment or
control group. The subjects took either 1 Lung Support Formula capsule or a placebo capsule twice a day for
12 weeks. All subjects were followed-up every 4 weeks to perform investigative and clinical examinations. Repeated
measure of analysis of variance was employed to compare the trend of respiratory symptoms scores between the
2 groups during 12 weeks of follow-up.
Results: Fifty patients from the treatment group and 49 patients in the control group completed the 3-month
follow-up. No adverse events were reported in the treatment duration. The percentage of patients reported to have
chronic cough, chronic expectoration and chronic bronchitis were significantly decreased in the treatment group
when compared with baseline after a 3-month intervention (P < 0.05). The respiratory symptoms scores declined
gradually with the lapse of time (P < 0.05) in the treatment group and there were no significant changes in the
control group by repeated measure of analysis of variance (P > 0.05).
Conclusions: The clinical research shows that use of Lung Support Formula shows significant improvements of
respiratory symptoms and is well-tolerated in short-term use among older adults. An additional study involving
more subjects and longer-term follow-up would be needed to provide convincing evidence of the improvement of
respiratory symptoms in the treatment group.* Correspondence: shirong61@yahoo.com.cn; jrao@mednet.ucla.edu
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Smoking and air pollution are major causes of respiratory
problems such as chronic bronchitis and other respiratory
syndromes [1,2]. Indoor and outdoor air pollution such as
cooking smoke [3], traffic and industrial pollutants are
some of the most serious environmental and public health
problems in the industrialized world [4,5], which contrib-
utes to the prevalence of respiratory symptoms including
chronic pharyngitis, laryngitis, tracheitis, bronchitis and
chronic obstructive pulmonary disease (COPD) [6,7]. With
the acceleration of industrialization in low or middle-
income nations, the problem is even more significant
now in China. Preliminary evidence was provided in
some research that elderly people might be more vul-
nerable to air pollution than younger adults [8,9]. Con-
temporary treatments with Western medicine, such as
anti-inflammatory regimens, etc., may be effective in reliev-
ing symptoms associated with chronic bronchitis, but may
have unexpected side effects [10-12]. Some natural prod-
ucts may be effective in improving respiratory functions,
yet their efficacies remain to be examined in randomized,
placebo-controlled studies [13-15].
Lung Support Formula is a nutritional supplement which
contains naturally derived Astragalus membranaceus,
Cordyceps sinensis, Ophiopogon japonicus, Panax ginseng,
Morus alba, Ginkgo biloba, Prunus armeniaca, Forsythia
suspensa, Salvia miltiorrhiza and Gekko gecko, plus vitamin
A, vitamin C, magnesium and zinc. The main ingredients
of Lung Support Formula are traditional herbs used for in-
vigoration, health preservation and reduction of fatigue in
Traditional Chinese Medicine for thousands of years [16].
Astragalus was used to strengthen the body and cordyceps
was verified that it could improve exercise performance
and might contribute to wellness in older subjects [15].
Ophiopogon was used to treat certain respiratory condi-
tions by stimulating production of mucus, making coughs
more productive. However, the benefits of this supplement
in relieving respiratory symptoms have not been reported
in a clinical setting. To evaluate the effects of Lung Support
Formula on improving respiratory symptoms in older
adults, we conducted a clinical study in Shanghai, China.
Methods
Study participants
Study subjects were recruited from the Health Service
Center of Sanlin community in Shanghai, China. The study
was reviewed and approved by the Internal Review Boards
of Sanlin Community Health Service Center, and all partic-
ipants gave written, informed consent before enrollment.
The criteria for including people in the study were as fol-
lows: 1) over 50 years old, either male or female; 2) had
symptoms like chronic cough, expectoration, dyspnea for
more than 1 month; 3) had chronic pharyngitis, laryngitis,
tracheitis, bronchitis or COPD. Enrolled patients musthave met the first criteria and any of the other two criteria
mentioned above. Subjects were excluded if they had any
history of: 1) cancer; 2) other serious diseases such as car-
diovascular disease, etc.; 3) acute inflammatory symptoms
or flu, etc.; 4) had used any prescription or OTC drugs to
treat respiratory disease recently (within the past 30 days).
Design and sample size
The present study was a double-blind, placebo-controlled
clinical trial. Subjects were provided with Lung Support
Formula or identical placebo capsules. The Lung Support
Formula capsules were manufactured following current
Good Manufacturing Practices (cGMP) guidelines by
Robinson Pharma, Inc. (Orange County, CA, USA). The
main ingredients of the Lung Support Formula capsules in-
cluded Astragalus membranaceus, Cordyceps sinensis,
Ophiopogon japonicus, Panax ginseng, Morus alba,
Ginkgo biloba, Prunus armeniaca, Forsythia suspensa,
Salvia miltiorrhiza, Gekko gecko, vitamin A, vitamin C,
magnesium and zinc. The placebo was also manufactured
by Robinson Pharma with the main ingredients being
Calcium, Maltodextrin, and Rice Flour.
The sample size was calculated according to our hy-
pothesis that the incidence of chronic cough (P1) in the
control group is 90%. The incidence in the intervention
group (P2) decreased to 70%. We set α level as 0.05,
β level as 20%. The pretest probability (1-β) was 90%. The
formula used to calculate sample size is shown below:
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The sample size would need to be 94 patients at least,
and thus, 47 patients in each group.
Randomization and grouping
A total of 100 patients were recruited and everyone
signed the informed consent form. Using a predetermined
randomization code via a random number generator, par-
ticipants were blindly randomized into either the treatment
or control group, with 50 patients in each group. The ran-
dom numbers were placed in sealed envelopes, and a serial
number was assigned to each envelope according to the se-
quence of allocation of the randomized number [17]. Each
envelope was opened sequentially, according to the admis-
sion sequence of subjects at the research center. Subjects
as well as physicians and nurses were blinded to the pa-
tients’ allocation. Each subject received a container marked
with different colored labels (e.g., green or white) with 60
capsules (1000 mg each) inside. Detailed instructions of ad-
ministrating the capsules were given to all patients. Each
subject took 1 color-coded capsule orally twice a day with
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the end of the study by the Sponsor. After randomization,
trained physicians were responsible for performing the
clinical examinations, ordering and interoperating labora-
tory testing, and conducting investigations.
Outcome measures
1) Patients’ basic information: age, sex, ethnicity, past
medical history, current drug/medication use,
drinking history, clinical diagnosis and the course
time, family history.
2) Primary outcome measures (followed-up once before
the intervention and 3 times after respectively): Five
respiratory symptoms included chronic cough,
chronic expectoration, asthma/dyspnea, chronic
angina and chronic bronchitis or bronchitis. The
respiratory symptoms scores were measured using a
5-point Likert scale which was divided (none, mild,
moderate, severe and very serious) and labeled 1–5,
respectively (Cronbach’s Alpha 0.71). The scores for
each symptom were then added up as the
respiratory symptoms scores (5–25). The higher the
score, the more serious the respiratory symptoms. It
can be considered as the main clinical index that
results in the severity of the respiratory symptom.
3) Secondary outcome measures: Laboratory blood
examinations and health survey (SF-36) evaluation
(at the beginning and the end of the intervention). A
standardized form was used to record the findings.
Monitoring of patients
All subjects were asked to return to the clinic on a weekly
basis for the first month and on a monthly basis for the
remaining 3 months. The following tasks were performed
at the time of each return visit: 1) any concerns that sub-
jects may have were answered; 2) compliance and toxicity
were evaluated; 3) capsules were resupplied.
Any serious and unexpected adverse events associated
with the capsules were reviewed and examined carefully
by the study physician and an unbiased written report of
the event within 10 calendar days of the initial reporting
was issued to the local health authority. At the mini-
mum, the physician commented on the outcomes of the
adverse event and relationships of the adverse event to
the test protocol.
Statistical analysis
Statistical data analyses were carried out using SPSS
Version 11 (SPSS Inc., Chicago, IL, USA). Normality of
distribution of all continuous variables was explored by
a Kolmogorov–Smirnov test. A 2-group Student’s t-test
or Mann–Whitney test was used to compare difference
in means or mean ranks of variables between the controlgroup and treatment group from baseline data. Chi-
squared (χ2) test was used to compare categorical variables.
For the comparison of the trend of respiratory symptoms
scores between the 2 groups during 3 months of follow-up,
repeated measure of analysis of variance were employed.
All tests were 2-sided and a P value of less than 0.05 was
considered to be statistically significant.
Result
Baseline data
One hundred subjects were recruited in this study, but 1
patient in the control group withdrew, leaving a total of
99 patients who completed the study: 50 patients in the
treatment group and 49 patients in the control group. The
baseline characteristics of patients regarding gender, age,
history of taking medications, history of smoking, history
of drinking, respiratory symptoms, physical examination,
experimental detection index and SF-36 evaluation were
comparable between the 2 groups (Table 1).
The comparison between the 2 follow-up groups on the
effects of the residual drug
As shown in Table 2, the comparison of residual drug
between the 2 groups had no statistical difference both
in 1 month and 2 months follow-up (P > 0.05).
The comparison between the 2 follow-up groups of
respiratory symptoms before and after intervention
As shown in Table 3, after a 3-month intervention, the per-
centage of patients reported to have chronic cough,
chronic expectoration and chronic bronchitis were signifi-
cantly decreased in the treatment group when compared
with baseline. The percentage of patients reported to have
chronic expectoration was also decreased in the control
group. The improvement of chronic cough was also signifi-
cant in the treatment group versus the control group. No
significant difference was found for other respiratory symp-
toms between the 2 groups after a 3-month intervention.
No serious or unexpected events associated with the cap-
sules were found in the intervention.
Repeated measurements comparison of respiratory
symptoms scores
Respiratory symptoms were assessed and scored 4 times:
1) at enrollment baseline; 2) 1-month follow-up; 3) 2-
month follow-up; 4) and the end of follow-up. Repeated
measure of analysis of variance was used to assess the
effect of change with the lapse of time after treatment
and the effects of treatment in the intervention and con-
trol groups. There were differences (P = 0.002) among
repetitive measurement of the treatment group at 4 time
points, the scores declined gradually with the lapse of time,
and kept stable (P < 0.001) after 2 months follow-up. The
follow-up score changes also had statistical significance
Table 1 Comparison of the baseline data between treatment and control group
Items Treatment group (n = 50) Control group (n = 49) P value*
Age (years) 64.33 ± 9.41 65.90 ± 10.73 0.436
Gender (male % ) 21/50 (42.0) 23/49 (46.9) 0.621
Medication history (positive %) 10/50 (20.0) 6/49 (12.2) 0.295
Smoking history (positive %) 7/50 (14.0) 9/49 (18.4) 0.555
Drinking history (positive %) 11/50 (22.0) 6/49 (12.2) 0.198
Respiratory symptoms score 8.86 ± 2.15 8.92 ± 2.33 0.897
Chronic cough (positive %) 46/50 (92.0) 47/49 (95.9) 0.692
Chronic expectoration (positive %) 43/50 (86.0) 43/49 (87.8) 0.796
Asthma/Dyspnea (positive %) 14/50 (28.0) 18/49 (36.7) 0.353
Chronic angina (positive %) 20/50 (40.0) 19/49 (38.8) 0.901
Chronic bronchitis (positive %) 31/50 (62.0) 27/49 (55.1) 0.486
Respiratory rate (times/min) 19.78 ± 2.33 20.33 ± 2.07 0.220
Heart rate (times/min) 80.10 ± 6.99 81.22 ± 6.99 0.426
HGB (mg/dL) 133.56 ± 12.43 129.65 ± 11.51 0.108
RBC (10 [9]/mm [3]) 4.51 ± 0.47 4.43 ± 0.54 0.418
WBC (10 [9]/mm [3]) 6.35 ± 1.34 6.69 ± 1.21 0.188
Neutrophil (10 [9]/mm [3]) 4.49 ± 1.20 4.76 ± 1.21 0.261
Scores of life quality (SF-36) 109.98 ± 16.33 107.94 ± 13.09 0.596
HGB, Hemoglobin; RBC, Red blood cell; WBC, white blood cell.
*Unpaired Student’s t-test or Mann–Whitney test was used to compare differences in mean or mean ranks of variables between the control group and treatment
group. Chi-square test was used for categorical data.
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nificant score changes with the lapse of time in the control
group (P = 0.082), but compared with the baseline, the first
scores after 1 month of the control group were lower and
remained stable after 1 month. The cause of the score de-
cline may be due to the placebo effect. There were no sig-
nificant differences between the 2 groups by test of
between-subjects effects of repeated measure (P = 0.409)
(Table 4 and Figure 1).
Discussion
Chinese herbal medicine has become increasingly popu-
lar around the world for the promotion of health andTable 2 Comparison between 2 groups of residual drug
in 1 month and 2 months follow-up
Residual
drug









0 capsules 25(50.0) 20(40.8) 38(76.0) 31(63.3)
1-5 capsules 17(34.0) 23(46.9) 6(12.0) 10(20.4)
6-12capsules 8(16.0) 6(12.2) 6(12.0) 8(16.3)
Total 50(100.0) 49(100.0) 50(100.0) 49(100.0)
Z / P value* 0.547/ 0.584 1.298/ 0.194
* Mann–Whitney test was used to compare differences of mean rank between
the control group and treatment group.adjuvant therapy [18-20]. To our knowledge, this pro-
spective clinical research was the first study to assess the
effects of Lung Support Formula, the nutritional supple-
ment containing natural Chinese herbs, on the improve-
ment of respiratory symptoms in older adults. The
findings from this study suggested that Lung Support
Formula might be beneficial to older adults by improving
respiratory symptoms. The treatment was well-tolerated
and none of the observed adverse events were considered
drug related. There were obvious improvements in the
respiratory symptoms in the treatment group; the total
scores show a decreasing tendency with progress of drug
taking, and the severity of symptoms presented a ten-
dency to be gradually relieved. Based on the concrete
symptoms, Lung Support Formula is useful for improv-
ing chronic cough, chronic expectoration and chronic
bronchitis or bronchitis, but the efficacy of improving
asthma, dyspnea and chronic angina is not obvious. Pla-
cebo effect was found in the control group; the total scores
of respiratory symptoms decreased significantly after the
first follow-up, but remained stable in the subsequent
follow-up. This suggested that the placebo effect played a
role in the subjective effect of the symptom scores and the
change of scores were significant, but the placebo effect
kept the symptom scores stable as treatment progressed.
The scores of the treatment group improved gradually with
supplement administration at the same period.
Table 3 Comparison of positive respiratory symptoms









Baseline 46/50 (92.0) 47/49 (95.9) 0.692
3 month after 38/50 (76.0)* 45/49 (91.8) 0.032#
Chronic expectoration
(positive %)
Baseline 43/50 (86.0) 43/49 (87.8) 0.796
3 month after 35/50 (70.0)* 37/50 (75.5)* 0.538
Asthma/Dyspnea
(positive %)
Baseline 14/50 (28.0) 18/49 (36.7) 0.353
3 month after 12/50 (24.0) 15/49 (30.6) 0.460
Chronic angina
(positive %)
Baseline 20/50 (40.0) 19/49 (38.8) 0.901
3 month after 21/50 (42.0) 16/49 (32.7) 0.336
Chronic bronchitis
(positive %)
Baseline 31/50 (62.0) 27/49 (55.1) 0.486
3 month after 25/50 (50.0)* 26/49 (53.1) 0.761
* P < 0.05 when comparing these variables before versus after intervention in
the treatment group or control group by using paired sample chi-square.
# P < 0.05 when comparing these variables between treatment group and
control group by using chi-square.
Figure 1 Comparison of respiratory symptoms scores
between groups.
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multiple pharmacological properties, including Astragalus
membranaceus, Cordyceps sinensis, Ophiopogon japonicus,
Panax ginseng, Morus alba and Ginkgo biloba, plus vita-
min A , vitamin C, magnesium and zinc which may pro-
vide greater clinical effectiveness with fewer side effects
than compound-based drugs [21]. As the main pharmaco-
logical property of the Lung Support Formula capsules As-
tragalus membranaceus is used in Traditional Chinese
Medicine and has been asserted to be a tonic that can im-
prove lung functions, promote healing, and reduce fatigue
[22]. Astragalus membranaceus has antibacterial and anti-
inflammatory properties. In addition, a study has shownTable 4 The comparison of respiratory symptoms scores betw
of analysis of variance (x  s)
Group Baseline One month follow-up Two m
Treatment 8.86 ± 2.15 8.24# ± 2.33
Control 8.92 ± 2.33 8.36 ± 2.00
F P 0.689 0.409 —
* P < 0.01 when assessing the effect of change with the lapse of time by using repe
# P < 0.05 when comparing the scores of follow-up versus of baseline by using pairthat astragalus has antiviral properties and stimulates the
immune system, suggesting that it may help prevent colds
and treat respiratory infections [23]. Cordyceps sinensis is
another primary ingredient, which is a potentially ergo-
genic herb that has been used in Chinese folk medicine for
centuries, primarily as a “lung invigorator” [24]. Studies
have identified potential performance-enhancing benefits
of cordyceps, including increased ventilation capacity [15]
and improved glucose metabolism [25]. Ophiopogon
japonicus is an important traditional Chinese herbal medi-
cine and has many health benefits in treating a wide range
of disorders [26]. Herbalists use ophiopogon to treat cer-
tain respiratory conditions because it is known to stimulate
production of mucus, making coughs more productive. As
we know, minor infections, especially infections like viral
bronchitis, which cannot be treated with antibiotics, can be
more easily cleared out of the respiratory tract if a patient
has a productive cough. Current research also finds that
saponin from ophiopogon can be explored as a novel and
potential natural immunostimulant that may have several
kinds of bioactivities, such as antiviral, anti-inflammatory,
antiparasitic, immune-enhancing, anticancer, and anti-
microbial activities [27]. Panax ginseng is a popular herbal
remedy that has been used for thousands of years. It has
been an important part of the pharmacopoeia of Trad-
itional Chinese Medicine and is classified as an adaptogeneen treatment and control group by repeated measure
onth follow-up End of follow-up F P*
7.82# ±1.88 7.92# ±1.99 6.582 0.002*
8.45 ± 2.41 8.39 ± 2.33 2.279 0.082
— — —
ated measure of analysis of variance.
ed sample t-test.
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stress and infection [28]. A research study demonstrated
that ginsenoside, an essential constituent of Chinese anti-
asthmatic herbal medicine and aphrodisiacs, relaxes hu-
man bronchial smooth muscle presumably through a
stimulation of nitric oxide generation by airway epithelium
[29]. These 4 primary ingredients of Lung Support For-
mula are all beneficial to reduce respiratory symptoms.
Among the strengths of our research was the fact that
it was a clinical study with a 3-month follow-up,
allowing for more precise estimation of effects. However,
the present study had several limitations. First, the sam-
ple size of our research was relatively small and the dur-
ation of study was not long enough; larger multicentre
and longer-term treatment studies are warranted to ver-
ify the effects of Lung Support Formula. Second, one of
the primary outcome measures was the respiratory
symptom scores developed by a 5-point Likert scale,
which was based on self-reporting by patients, who
might underreport or overreport their symptoms. This
bias cannot be determined from the data without object-
ive measurements as in other studies [4,30,31], however,
reliability study (Cronbach’s Alpha coefficient) had indi-
cated good fitness results for the evaluation of respira-
tory symptom scores in our research.
Despite these limitations, the current study provides
evidence of the improvement of respiratory symptoms
among older adults by taking Lung Support Formula.
Findings also indicate this natural product with multiple
pharmacological properties is safe.
Conclusions
This clinical research lends support to the hypothesis
that the proprietary formula, Lung Support Formula,
which contains naturally derived Chinese herbal medi-
cines will lead to a significant improvement of respira-
tory symptoms and is well-tolerated in short-term use
among older adults. An additional study involving more
subjects and longer-term follow-up would be needed to
provide convincing evidence of the improvement of re-
spiratory symptoms in the treatment group.
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